Platinum(iv) oxaliplatin-peptide conjugates targeting memHsp70+ p.pdf (768.37 kB)
Platinum(iv) oxaliplatin-peptide conjugates targeting memHsp70+ phenotype in colorectal cancer cells.
Version 2 2022-04-01, 10:45
Version 1 2019-11-23, 11:48
journal contribution
posted on 2019-11-23, 11:48 authored by Aoife M. McKeon, Janis Noonan, Marc Devocelle, Brona M. Murphy, Darren M. GriffithNovel Pt(iv) tumour penetrating peptide (TPP) conjugates are reported. They are the first example of metallodrugs to target a membrane bound heat shock protein 70 positive (memHSP70+) phenotype in cancer cells. The conjugates exhibit superior cytotoxicity as compared to oxaliplatin alone in Pt resistant colorectal cancer cells with relatively high memHSP70+ expression. Substitution of TPP in Pt(iv) peptide conjugates with scrambled peptide (ScP) essentially abolishes the observed cytotoxicity.
Funding
Science Foundation Ireland (SFI) under Grant Number 12/IP/1305
History
Comments
This article is also available at http://pubs.rsc.org/en/Content/ArticleLanding/2017/CC/C7CC04764A#!divAbstractPublished Citation
McKeon AM, Noonan J, Devocelle M, Murphy BM, Griffith DM. Platinum(iv) oxaliplatin-peptide conjugates targeting memHsp70+ phenotype in colorectal cancer cells. Chemical Communications. 2017;53(82):11318-11321.Publication Date
2017-10-12Publisher
Royal Society of ChemistryExternal DOI
PubMed ID
28967013Usage metrics
Categories
No categories selectedKeywords
Licence
Exports
RefWorks
BibTeX
Ref. manager
Endnote
DataCite
NLM
DC